Search

Displaying results 5531 - 5540 of 6278 in total
  1. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777]

  2. Drug

    Dapansutrile

    go.drugbank.com/drugs/DB16130
    Investigational

    Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

  3. Drug

    Desidustat

    go.drugbank.com/drugs/DB16135
    Investigational

    Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).

  4. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

  5. Drug

    Azosemide

    go.drugbank.com/drugs/DB08961
    Investigational

    Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

  6. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  7. Drug

    Daxdilimab

    go.drugbank.com/drugs/DB16391
    Investigational

    Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).

  8. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a ...

  9. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

  10. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.